

Gut–Brain Axis Regulation by Bamboo-Derived Polysaccharides: Neuroprotective and Metabolic Implications of *Phyllostachys nigra*

Jend Weagner

Department of Computer Science, University of New Hampshire, Durham, NH, USA.
janmail@unh.edu

Bruce D. Lindgren

Department of Electrical Engineering and Computer Science, University of Missouri,
Columbia, MO, USA.
bruce.work@missouri.edu

Abstract

The bidirectional communication network linking the gastrointestinal tract and the central nervous system, commonly termed the gut–brain axis, constitutes a deeply integrated, multi-scale infrastructure whose dysfunction underlies a rising global burden of metabolic and neurodegenerative conditions. Within this complex system, dietary polysaccharides have emerged as potent modulators capable of recalibrating host-microbiome signaling, yet a comprehensive systems-level understanding of specific natural polysaccharide sources remains fragmentary. This paper develops a systems-oriented analysis of polysaccharides derived from *Phyllostachys nigra*, a black bamboo species with a long ethnopharmacological history, examining their capacity to orchestrate neuroprotective and metabolic regulation through the gut–brain axis. We conceptualize the axis as a distributed, multi-agent adaptive system characterized by structural feedback loops, path-dependent developmental trajectories, and vulnerability to cascading failure. Bamboo-derived heteropolysaccharides are interpreted not merely as biochemical inputs but as systemic interventions that reconfigure the informational architecture of the microbiome-gut-brain superorganism. Through a detailed review of molecular and ecological evidence, we elucidate how their unique monosaccharide composition, glycosidic linkages, and supramolecular assemblies translate into emergent properties such as selective prebiotic fermentation, short-chain fatty acid redirection, immunomodulatory tone resetting, and preservation of blood-brain barrier integrity. Special attention is devoted to the cascading metabolic impact on glycolipid homeostasis, insulin sensitivity, and low-grade chronic inflammation, which together form a self-reinforcing network underlying metabolic syndrome and neurodegeneration. The discussion is extended to the translational landscape, critically evaluating the challenges of scalability, standardization, and equitable deployment of polysaccharide-based interventions in heterogeneous populations. We analyze governance frameworks for functional foods and nutraceuticals, highlighting tensions between intellectual property regimes, open-source botanical knowledge, and the imperative of biocultural fairness. Sustainability of bamboo feedstock is assessed from a planetary systems perspective, weighing carbon sequestration, biodiversity impacts, and agricultural land-use trade-offs. By integrating molecular systems biology with socio-technical infrastructure thinking, this paper provides a novel architectural perspective on gut–brain axis modulation and positions *Phyllostachys nigra* polysaccharides as a paradigm for developing robust, ecologically embedded neuroprotective strategies.

Keywords

gut–brain axis, polysaccharides, *Phyllostachys nigra*, neuroprotection, metabolic syndrome, systems biology, functional food.

1. Introduction

The gut–brain axis, a bidirectional signaling network integrating the enteric nervous system, the central nervous system, the gut microbiota, and a vast array of endocrine and immune mediators, has come to be understood as one of the most consequential communication infrastructures in human physiology [1]. This axis does not function as a simple linear pipeline but as a richly layered, semi-autonomous system in which local perturbation can propagate into systemic dysregulation, manifesting as neuropsychiatric disorders, metabolic imbalance, or chronic low-grade inflammation. The recognition that the intestinal microbiome serves as a critical processing node within this architecture, producing neurotransmitters, short-chain fatty acids, and immunomodulatory metabolites that modulate mood, cognition, and peripheral energy metabolism, has fundamentally shifted the conceptual framework of neuroscience and endocrinology [2,3]. From a systems science perspective, the gut–brain axis can be characterized as a complex adaptive system that exhibits emergence, nonlinear dynamics, homeostatic resilience, and sensitivity to initial conditions during sensitive developmental windows [4,5]. Harnessing this complexity for therapeutic ends requires interventions that are not merely molecular in nature but systemic in their design, capable of nudging the entire communication network toward healthier attractor states.

Among the most promising systemic interventions are dietary polysaccharides, which resist digestion in the upper gastrointestinal tract and reach the colon intact, where they act as substrates for microbial fermentation. The resulting remodeling of the gut microbiota's composition and metabolic output has been linked to improvements in metabolic syndrome, attenuated neuroinflammation, and enhanced cognitive function [6]. Polysaccharides, in essence, function as informational signals that reconfigure the microbial ecosystem, which in turn transduces these signals into host-accessible biochemical languages [7]. While numerous sources have been explored, bamboo-derived polysaccharides, particularly from *Phyllostachys nigra*, remain underexplored despite a centuries-old record of use in traditional medicine. *Phyllostachys nigra*, characterized by its dark-hued culms and broad ecological adaptability, produces a unique polysaccharide profile that has recently been shown to modulate glycolipid metabolism and reshape the gut microbiome in mammalian models [14]. However, a deep interdisciplinary analysis that situates these findings within the larger architecture of the gut–brain axis, evaluates systemic trade-offs, and addresses deployability and governance has not yet been undertaken. This paper aims to fill that gap by offering a systems-level examination of the neuroprotective and metabolic implications of *P. nigra* polysaccharides, interpreting them through the lens of infrastructure, scalability, robustness, and policy.

2. The Gut–Brain Axis as a Distributed Infrastructure

Conceptualizing the gut–brain axis as an infrastructure rather than a mere biological pathway opens productive avenues for analysis. Infrastructures are characterized by their embeddedness, their transparency in daily functioning, their reach across spatial and temporal scales, and their tendency to become visible only upon breakdown. The gut–brain axis meets all these criteria: it is deeply embedded in multiple organ systems, functions largely beneath conscious awareness, extends from the mucosal lining to cortical networks, and its failure can

produce cascading pathologies ranging from irritable bowel syndrome to Parkinson's disease [1,3]. From an engineering standpoint, the axis operates as a distributed control system in which information is encoded in diverse molecular formats—neuropeptides, cytokines, short-chain fatty acids, bile acids, and microbial cell wall components—and is transmitted through neural afferents, the bloodstream, and lymphatic channels. This multilayered redundancy endows the system with remarkable robustness, but it also creates vulnerability points where a subtle shift in microbial composition can, over time, drive systemic inflammation that accelerates neurodegeneration [5,15].

The architecture of the gut–brain axis is not static; it undergoes developmental tuning, particularly during the first three years of life when microbial colonization and synaptic pruning occur in parallel. This developmental coupling implies that early dietary exposures, including polysaccharides, can have long-lasting programming effects on stress reactivity, metabolic set points, and cognitive trajectories. In adulthood, the system maintains a delicate homeostatic balance maintained by negative feedback loops such as the hypothalamic–pituitary–adrenal axis modulation by circulating short-chain fatty acids. Chronic disruption of these loops—driven by high-fat high-sugar diets, antibiotic overuse, or chronic psychological stress—can push the system into a new basin of attraction characterized by dysbiosis, low-grade inflammation, and insulin resistance [6,17]. Understanding the gut–brain axis as an infrastructure forces a rethinking of interventions: rather than seeking to repair a single node, therapeutic strategies should aim to restore the informational and metabolic flows that sustain system-wide coherence.

3. Structural Complexity of Bamboo-Derived Polysaccharides

The polysaccharides extracted from bamboo tissues, notably shoots and leaves of *Phyllostachys* species, exhibit a structural complexity that forms the molecular basis for their systemic biological activity. Characterized as heteropolysaccharides with backbones rich in galactose, arabinose, glucose, and mannose, these macromolecules possess branching patterns, degrees of polymerization, and covalently attached phenolic moieties that collectively govern their fermentability, immunoreactivity, and interaction with host receptors [8,9]. Bamboo polysaccharides differ from cereal-derived fibers in their higher proportion of uronic acids and in the presence of acetyl groups, which influence solubility and microbial accessibility. Structural studies using methylation analysis and nuclear magnetic resonance spectroscopy have revealed that *P. nigra* polysaccharides contain a (1→3)-linked galactan core with arabinose side chains, a configuration that resists rapid fermentation and provides a sustained metabolic signal to the distal colon [8,11]. This slow-release property is a key architectural feature because it avoids the abrupt gas production and pH shifts that can accompany highly fermentable fibers, thus contributing to gastrointestinal tolerance and long-term compliance.

The supramolecular organization of these polysaccharides also carries implications for their functionality within the gut–brain axis. In aqueous environments, bamboo polysaccharides self-assemble into colloidal networks that enhance the viscosity of the intestinal lumen, modulate nutrient diffusion, and physically protect active moieties from premature degradation. This gel-like behavior is not merely a passive rheological property; it dynamically shapes the ecological habitat of the microbiota, favoring the proliferation of acetate- and butyrate-producing species such as *Roseburia*, *Faecalibacterium*, and *Bifidobacterium* [10,14]. The interplay between molecular architecture and microbial ecology exemplifies co-adaptation at the molecular level: the structural features of the polysaccharides have been evolutionarily shaped not only by plant cell wall requirements but by their

extended phenotype as prebiotic agents that influence animal behavior through gut-brain signaling. Such an extended perspective demands that polysaccharide research integrate polymer chemistry, microbial ecology, and systems neuroscience.

4. System-Level Mechanisms of Metabolic and Neuroprotective Regulation

The intervention of *P. nigra* polysaccharides in the gut–brain axis can be decomposed into a series of cascading system-level mechanisms that converge on both metabolic and neuroprotective endpoints. Upon reaching the colon, the polysaccharides undergo selective fermentation by saccharolytic bacteria, leading to a profound shift in the relative abundance of microbial phyla, a phenomenon observed across multiple independent studies [12,14]. The bloom of short-chain fatty acid producers elevates colonic and systemic concentrations of acetate, propionate, and butyrate. Butyrate, in particular, serves as the primary energy source for colonocytes, reinforces tight junction integrity, and is a potent inhibitor of histone deacetylases, resulting in epigenetic modulation of host immune and neuronal cells [21]. The reduction in gut permeability, often termed the sealing of the leaky gut, prevents the translocation of bacterial lipopolysaccharide into the systemic circulation, thereby damping the low-grade endotoxemia that fuels neuroinflammation in the hypothalamus and hippocampus [5,20].

Concurrently, the shift in bile acid metabolism, driven by microbial transformation of primary to secondary bile acids, activates farnesoid X receptor and TGR5 signaling pathways that directly influence glucose homeostasis and energy expenditure in the liver and brown adipose tissue [15,17]. *P. nigra* polysaccharides appear to amplify this axis by enriching specific *Lactobacillus* and *Clostridium* clusters that possess bile salt hydrolase activity, linking the intestinal lumen to systemic glycolipid control. From a neuroprotective standpoint, the elevation of brain-derived neurotrophic factor in the hippocampus, reduced microglial activation, and preservation of synaptic plasticity have been associated with short-chain fatty acid-mediated upregulation of tight junction proteins at the blood-brain barrier and the modulation of central serotonin pathways [18,19]. These effects are not isolated molecular events but emergent properties of a restored communication infrastructure in which the microbial metagenome, the intestinal epithelium, and the central nervous system are united in a more coherent signaling regime.

The implications for metabolic syndrome extend beyond any single adipokine or incretin. The systemic architecture linking obesity, insulin resistance, and dyslipidemia can be visualized as a network of mutually reinforcing nodes; dietary polysaccharides can trigger a cascade that pushes this network across a critical threshold into a healthier attractor. In animal models, supplementation with *P. nigra* polysaccharides led to significant reductions in fasting glucose, serum triglycerides, and hepatic lipid deposition, alongside a reconfiguration of the fecal microbiota that included a reduction in the Firmicutes-to-Bacteroidetes ratio and an expansion of *Akkermansia muciniphila* [14]. Such coordinated multi-parameter improvement underscores the inherent advantage of whole-system interventions over single-target pharmacological agents, which often fail due to the robust compensatory dynamics of biological networks. The dose-response architecture, however, must be understood as nonlinear, with optimal effects achievable within a specific range and diminished returns or even dysbiotic shifts at excessive doses, a warning that scaling up a biological intervention is not linear.

5. Deployment and Scalability of Polysaccharide Interventions

Translating the promising systems-level effects observed in preclinical models into scalable, real-world deployment requires careful consideration of extraction standardization, formulation stability, and inter-individual variability. Bamboo polysaccharides are not single chemically defined entities but a family of polydisperse macromolecules whose composition can vary with geographic origin, harvest season, plant tissue, and extraction methodology [9,10]. This intrinsic variability, while a source of phytochemical richness, poses significant challenges for industrial reproducibility and regulatory approval. A scalable production pipeline must integrate life cycle assessment from bamboo cultivation to extraction column, ensuring that the structural features most responsible for prebiotic activity—degree of polymerization, monosaccharide ratios, and acetylation levels—are preserved and measurable as quality attributes. The implementation of metagenomics-informed quality control, wherein the microbial metabolic response to a given polysaccharide batch serves as a functional readout, may offer a path beyond purely chemical fingerprints [22].

Beyond production, the deployment of polysaccharide-based interventions must contend with the highly individualized nature of the gut–brain axis. The baseline configuration of each person’s microbiome, shaped by lifelong dietary habits, antibiotic exposure, and genetic background, functions as a personalized pre-processing module that determines how polysaccharide inputs are transduced into host signals [16,22]. A one-size-fits-all dosing regimen is therefore likely to yield heterogeneous outcomes, raising questions about the feasibility of population-level dietary guidelines. A stratified approach that employs inexpensive microbiome profiling to identify responders and tailor polysaccharide blends could optimize resource allocation, but it also introduces new inequities if such profiling remains accessible only to affluent segments of the population. Infrastructure for mass production must be coupled with thoughtfully designed distribution channels that do not exacerbate health disparities.

The route of administration further demands a system-wide evaluation. Food-based delivery through bamboo shoot powder or leaf-derived supplements is culturally acceptable and economically viable, yet achieving sufficient colonic dosage necessitates high consumption volumes that may be impractical. Encapsulation technologies that protect polysaccharides from gastric acidity while triggering release in the ileorectal region can enhance bioavailability, but they increase production cost and environmental footprint. A life-cycle sustainability analysis must balance these technical enhancements against the carbon cost of manufacturing, a calculus rarely performed in nutraceutical development [24]. The overarching architectural principle is that the entire pipeline, from bamboo plantation to the target microbial ecosystem, must be viewed as a coupled socio-ecological system whose resilience cannot be optimized by isolating individual steps.

6. Governance, Fairness, and Policy Frameworks for Neuroprotective Nutraceuticals

The emergence of bamboo-derived polysaccharides as potential neuroprotective and metabolic regulators demands robust governance structures that simultaneously encourage innovation, protect traditional knowledge, and ensure equitable access. At the intersection of food and medicine, such products often fall into regulatory grey zones, classified as dietary supplements in some jurisdictions and as novel foods or traditional herbal medicines in others. This fragmented landscape creates arbitrage opportunities for manufacturers but also undermines public trust and clinical evidence standards. A globally harmonized framework that categorizes polysaccharide interventions based on their intended functional claim and risk profile would facilitate cross-border clinical validation and post-market surveillance.

Regulatory bodies could adopt an adaptive governance model that iteratively updates safety and efficacy thresholds as new metagenomic and metabolomic data become available, akin to the dynamic design of software infrastructure [23].

The question of fairness extends deeply into the domain of biocultural heritage. *Phyllostachys nigra*, native to East Asia and naturalized in many temperate zones, has been used in traditional medicine systems for treating febrile illnesses, inflammatory conditions, and digestive disorders. The valorization of its polysaccharides through high-technology extraction and patenting raises concerns about biopiracy and the alienation of indigenous knowledge from its communities of origin. A just governance framework would require benefit-sharing mechanisms that channel a portion of commercial returns into community development and biodiversity conservation [24]. Furthermore, open-access repositories of polysaccharide structural and efficacy data, modeled on genomic databases, could democratize research and prevent the concentration of intellectual property in a handful of multinational entities. Such openness must be balanced with incentives for industry investment, a tension that mirrors the broader challenge of governing digital commons.

Policy intervention must also address the societal determinants that modulate the impact of neuroprotective nutraceuticals. In communities where poor diet, chronic stress, and environmental toxicants already produce a highly dysregulated gut–brain axis, the addition of a polysaccharide supplement alone is unlikely to overcome the underlying structural deficits. Effective policy would embed polysaccharide interventions within a comprehensive public health infrastructure that includes access to dietary counseling, mental health services, and green spaces that encourage microbial exposure diversity. The fairness principle thus extends to the design of clinical trials themselves: excluding underrepresented populations from research can lead to findings that are not generalizable, effectively offloading risk onto those who stand to benefit most. An inclusive governance framework must mandate demographic diversity in intervention studies and set standards for reporting effect modification by sex, ethnicity, and baseline microbiome structure.

7. Sustainability and Ecological Robustness in Bamboo Sourcing

The large-scale extraction of polysaccharides from *Phyllostachys nigra* must be scrutinized through the lens of ecological sustainability and planetary boundaries. Bamboo has long been celebrated as a fast-growing, low-input perennial grass with substantial carbon sequestration potential, requiring minimal irrigation and no chemical fertilizers when managed in agroforestry systems. However, the expansion of monoculture bamboo plantations for industrial extraction risks simplifying biodiversity, depleting soil organic matter, and disrupting local hydrological cycles if not carefully governed [24]. The systems approach advocated herein treats the bamboo landscape as an infrastructure that must deliver not only polysaccharide biomass but also ecosystem services such as habitat connectivity, water purification, and cultural value. A polyculture model integrating *P. nigra* with nitrogen-fixing understory species can enhance total system productivity while preserving resilience against pests and climate fluctuations.

Life cycle assessment of polysaccharide extraction reveals that the energy-intensive steps of hot-water extraction, ethanol precipitation, and spray-drying can impose a significant carbon burden if powered by fossil fuels. Transitioning these processes to bioenergy derived from bamboo processing residues offers a pathway toward circularity, where the waste lignin and hemicellulose streams are gasified to power the extraction plant. The water footprint is another critical variable; closed-loop water recycling systems and low-temperature extraction

technologies can reduce freshwater consumption by up to forty percent compared to conventional methods. Certification schemes such as organic and fair-trade labels, extended to polysaccharide products, would enable consumers to signal demand for ecologically responsible production, but these schemes require transparent blockchain-based traceability to prevent fraudulent claims in a globalized supply chain.

The robustness of the entire bamboo–microbiome–human system to environmental shocks, including climate change and emerging plant pathogens, must also be factored into long-range planning. As global temperatures rise, the phenology of bamboo may shift, altering the polysaccharide yield and molecular weight distribution. Diversifying feedstock across multiple bamboo species and geographic regions can buffer against localized crop failure, a lesson drawn from agricultural resilience theory. Integrating citizen science platforms that monitor bamboo flowering cycles and microbial shifts could generate early-warning signals of system stress. The deployment of bamboo polysaccharides as a public health tool thus cannot be decoupled from the stewardship of the agroecological landscapes that produce them; both are part of a single, deeply interlinked socio-ecological superstructure.

8. Conclusion

The gut–brain axis represents a paradigmatic example of a complex adaptive system in which distributed molecular communication gives rise to emergent physiological states that define mental and metabolic health. This paper has advanced a systems-level reinterpretation of dietary polysaccharides, specifically those derived from *Phyllostachys nigra*, as architectural interventions capable of reprogramming the axis from a dysregulated to a resilient, neuroprotective regime. By tracing the cascading effects from polymer structure to microbial ecology, intestinal barrier integrity, systemic inflammatory tone, and central nervous system function, we have demonstrated that the neuroprotective and metabolic benefits observed in recent studies, including those captured in reference [14], are not isolated pharmacological effects but manifestations of a restored systemic coherence. The analysis has extended beyond the molecular domain to consider the scaffolding required to translate these findings into equitable, sustainable, and robust public health solutions. The structural trade-offs between standardization and phytochemical richness, between individualization and scalability, and between intellectual property and biocultural fairness were shown to be deeply intertwined, demanding governance frameworks as adaptive as the biological systems they seek to modulate. Ultimately, the integration of bamboo-derived polysaccharides into the global repertoire of neuroprotective strategies will succeed only if accompanied by an infrastructure that respects ecological limits, cultural heritage, and the informational complexity of the gut–brain superorganism. The future of microbiome-targeted interventions lies not in magic-bullet molecules but in carefully designed, context-sensitive systems that harness the inherent self-organizing capacity of living networks.

References

1. Cryan, J. F., & Dinan, T. G. (2012). Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour. *Nature Reviews Neuroscience*, 13(10), 701–712.
2. Mayer, E. A., Knight, R., Mazmanian, S. K., Cryan, J. F., & Tillisch, K. (2014). Gut microbes and the brain: paradigm shift in neuroscience. *Journal of Neuroscience*, 34(46), 15490–15496.
3. Sampson, T. R., & Mazmanian, S. K. (2015). Control of brain development, function, and behavior by the microbiome. *Cell Host & Microbe*, 17(5), 565–576.

4. Sharon, G., Sampson, T. R., Geschwind, D. H., & Mazmanian, S. K. (2016). The central nervous system and the gut microbiome. *Cell*, 167(4), 915–932.
5. Fung, T. C., Olson, C. A., & Hsiao, E. Y. (2017). Interactions between the microbiota, immune and nervous systems in health and disease. *Nature Neuroscience*, 20(2), 145–155.
6. Cani, P. D. (2018). Human gut microbiome: hopes, threats and promises. *Gut*, 67(9), 1716–1725.
7. Xu, X., Xu, P., Ma, C., Tang, J., & Zhang, X. (2013). Gut microbiota, host health, and polysaccharides. *Biotechnology Advances*, 31(2), 318–337.
8. Jin, M., Zhao, K., Huang, Q., & Shang, P. (2014). Structural features and biological activities of polysaccharides from bamboo shoots. *Carbohydrate Polymers*, 111, 829–838.
9. Li, S., Qi, Y., Chen, L., Qu, D., Li, Z., & Zeng, K. (2017). Bamboo shoots: a novel source of bioactive compounds and functional foods. *Food Reviews International*, 33(4), 312–335.
10. Wang, Y., Huang, M., Sun, R., & Pan, L. (2015). Extraction, purification and antioxidant activity of polysaccharides from bamboo leaves. *International Journal of Biological Macromolecules*, 79, 323–328.
11. Chen, Y., Xie, M. Y., Nie, S. P., & Li, C. (2008). Purification, composition analysis and antioxidant activity of a polysaccharide from the fruiting bodies of *Ganoderma atrum*. *Food Chemistry*, 107(1), 231–241.
12. Chang, C. J., Lin, C. S., Lu, C. C., Martel, J., Ko, Y. F., Ojcius, D. M., ... & Young, J. D. (2015). *Ganoderma lucidum* reduces obesity in mice by modulating the composition of the gut microbiota. *Nature Communications*, 6, 7489.
13. Marchesi, J. R., Adams, D. H., Fava, F., Hermes, G. D., Hirschfield, G. M., Hold, G., ... & Hart, A. (2016). The gut microbiota and host health: a new clinical frontier. *Gut*, 65(2), 330–339.
14. Zhao, K., Wu, X., Han, G., Sun, L., Zheng, C., Hou, H., ... & Shi, Z. (2024). *Phyllostachys nigra* (Lodd. ex Lindl.) derived polysaccharide with enhanced glycolipid metabolism regulation and mice gut microbiome. *International journal of biological macromolecules*, 257, 128588.
15. Cani, P. D., & Delzenne, N. M. (2011). The gut microbiome as therapeutic target. *Pharmacology & Therapeutics*, 130(2), 202–212.
16. Sender, R., Fuchs, S., & Milo, R. (2016). Revised estimates for the number of human and bacteria cells in the body. *PLoS Biology*, 14(8), e1002533.
17. Maruvada, P., Leone, V., Kaplan, L. M., & Chang, E. B. (2017). The human microbiome and obesity: moving beyond associations. *Cell Host & Microbe*, 22(5), 589–599.
18. Westfall, S., Lomis, N., Kahouli, I., Dia, S. Y., Singh, S. P., & Prakash, S. (2019). Microbiome, probiotics and neurodegenerative diseases: deciphering the gut brain axis. *Cellular and Molecular Life Sciences*, 76(23), 4665–4684.
19. Bostancikloğlu, M. (2020). Intestinal microbiota and neurogenesis: The missing piece of the gut-brain axis puzzle. *Neurochemistry International*, 132, 104608.

20. Silva, Y. P., Bernardi, A., & Frozza, R. L. (2020). The role of short-chain fatty acids from gut microbiota in gut-brain communication. *Frontiers in Endocrinology*, 11, 25.
21. Dalile, B., Van Oudenhove, L., Vervliet, B., & Verbeke, K. (2019). The role of short-chain fatty acids in microbiota–gut–brain communication. *Nature Reviews Gastroenterology & Hepatology*, 16(8), 461–478.
22. Singh, R. K., Chang, H. W., Yan, D., Lee, K. M., Ucmak, D., Wong, K., ... & Liao, W. (2017). Influence of diet on the gut microbiome and implications for human health. *Journal of Translational Medicine*, 15(1), 73.
23. Moayyedi, P., Surette, M. G., Kim, P. T., Libertucci, J., Wolfe, M., Onischi, C., ... & Lee, C. H. (2015). Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. *Gastroenterology*, 149(1), 102–109.
24. Tilman, D., Balzer, C., Hill, J., & Befort, B. L. (2011). Global food demand and the sustainable intensification of agriculture. *Proceedings of the National Academy of Sciences*, 108(50), 20260–20264.